Extended Data Fig. 3: NAbT against WT SARS-CoV-2 and VOCs in haematological and solid cancer types.
a) Comparison of NAbT WT SARS-CoV-2 and the three VOCs by cancer type in infection-naive patients with haematological malignancies (At BL/FU3: CLL: 3/11, MDS/MPN:5/4, Lymphoma: 23/28, Acute Leukaemia:16/13, Myeloma:8/19, 1 patient with aplastic anaemia not included in analysis) and b) solid tumours (At BL/FU3: Genitourinary: 56/51,GI: 35/34,Thoracic: 49/38,Gynae: 16/13, Solid_other: 13/14, H&N: 8/5, Breast: 26/26, Skin: 59/51). Dotted line at <40 denotes the lower limit of detection, dotted line at >2560 denoted the upper limit of detection. Violin plots denote density of data points. Pointrange denotes the median and the 25 and 75 percentiles. Dots represent individual samples. Significance post-second dose was tested by Kruskal Wallis test, p < 0.05 was considered significant, post-hoc test: two-sided Wilcoxon Mann-Whitney U test with Bonferroni correction was used for pairwise comparisons. Only comparisons with an adjusted p-value < 0.05 are denoted in the graph. * p < 0.05, ** p < 0.01, *** p < 0.001. GI, Gastrointestinal; Gynae, Gynaecological; H&N, Head & Neck; BL, baseline; FU3, 14-28days post second-vaccine.
